Exact Mass: 440.1319
Exact Mass Matches: 440.1319
Found 146 metabolites which its exact mass value is equals to given mass value 440.1319
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ginkgolide C
Ginkgolide C is found in fats and oils. Ginkgolide C is a bitter principle from Ginkgo biloba (ginkgo). Bitter principle from Ginkgo biloba (ginkgo). Ginkgolide C is found in ginkgo nuts and fats and oils. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease.
S-[(Z)-N-hydroxy(4-hydroxyphenyl)acetimidoyl]glutathione
Ginkgolide
ginkgolide-C is a natural product found in Ginkgo biloba with data available. See also: Ginkgo (part of). Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease.
Tetrahydroswertianolin
A xanthone glycoside that is the 1,2,3,4-tetrahydro derivaive of swertianolin (the S,4R-stereoisomer). It is isolated from Swertia japonica and shows hepatoprotective properties.
8,9-Dimethoxy-2-(2-phenyldiazenyl)-3-(2-thienyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile
5-O-beta-D-glucopyranosyl-2,3-dihydrooroselol|peucedanoside B
1-caffeoyl-6-tuliposide A|1-O-caffeoyl-6-O-(4-hydroxy-2-methylenebutyroyl)-beta-D-glucopyranose
(6-cis-p-coumaroyl)-3-O-beta-D-glucopyranosyl-2-deoxy-D-ribono-gamma-lactone
3,10-diacetoxy-1,2;8,9-diepoxy-2,3,6a,7,9,10,13a,14-octahydro-1H,8H-7a,14a-cyclo-pyrazino[1,2-a;4,5-a]diindole-6,13-dione|O,O-diacetyl-scabrosine|Scabrosin-4,4-diacetat
(1S,3R,6R,7S,8S,9R,10S,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.0¹,¹¹.0³,⁷.0⁷,¹¹.0¹³,¹⁷]nonadecane-5,15,18-trione
Ginkgolide C
Annotation level-1 Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease. Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease.
(1S,3R,6R,7S,8S,9R,10S,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.0¹,¹¹.0³,⁷.0⁷,¹¹.0¹³,¹⁷]nonadecane-5,15,18-trione_major
(1S,3R,6R,7S,8S,9R,10S,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.0¹,¹¹.0³,?.0?,¹¹.0¹³,¹?]nonadecane-5,15,18-trione
Cys Cys Cys Ile
Cys Cys Cys Leu
Cys Cys Ile Cys
Cys Cys Leu Cys
Cys Asp Phe Gly
Cys Asp Gly Phe
Cys Phe Asp Gly
Cys Phe Gly Asp
Cys Gly Asp Phe
Cys Gly Phe Asp
Cys Gly Met Met
Cys Ile Cys Cys
Cys Leu Cys Cys
Cys Met Gly Met
Cys Met Met Gly
Cys Met Ser Thr
Cys Met Thr Ser
Cys Ser Met Thr
Cys Ser Thr Met
Cys Thr Met Ser
Cys Thr Ser Met
Asp Cys Phe Gly
Asp Cys Gly Phe
Asp Phe Cys Gly
Asp Phe Gly Cys
Asp Gly Cys Phe
Asp Gly Phe Cys
Phe Cys Asp Gly
Phe Cys Gly Asp
Phe Asp Cys Gly
Phe Asp Gly Cys
Phe Gly Cys Asp
Phe Gly Asp Cys
Gly Cys Asp Phe
Gly Cys Phe Asp
Gly Cys Met Met
Gly Asp Cys Phe
Gly Asp Phe Cys
Gly Phe Cys Asp
Gly Phe Asp Cys
Gly Met Cys Met
Gly Met Met Cys
Ile Cys Cys Cys
Leu Cys Cys Cys
Met Cys Gly Met
Met Cys Met Gly
Met Cys Ser Thr
Met Cys Thr Ser
Met Gly Cys Met
Met Gly Met Cys
Met Met Cys Gly
Met Met Gly Cys
Met Ser Cys Thr
Met Ser Thr Cys
Met Thr Cys Ser
Met Thr Ser Cys
Ser Cys Met Thr
Ser Cys Thr Met
Ser Met Cys Thr
Ser Met Thr Cys
Ser Thr Cys Met
Ser Thr Met Cys
Thr Cys Met Ser
Thr Cys Ser Met
Thr Met Cys Ser
Thr Met Ser Cys
Thr Ser Cys Met
Thr Ser Met Cys
His-Tyr-OH
(4R)-5-(8-azaspiro[4.5]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid
1-[(4-chlorophenyl)-phenylmethyl]-4-(4-methylphenyl)sulfonylpiperazine
4-Thiazolidinecarboxylic acid, 3-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]-2,2-dimethyl-, (4R)-
3-(N-Morpholino)propanesulfonic acid hemisodium salt
GSK 2018682
2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-N-(2-furanylmethyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide
N2-({[(4-Bromophenyl)methyl]oxy}carbonyl)-N1-[(1S)-1-formylpentyl]-L-leucinamide
(2S)-2-amino-5-[[(1R)-1-carboxy-2-[(1,2,6-trimethyl-3,5-dioxopyrazolo[1,2-a]pyrazol-7-yl)methylsulfanyl]ethyl]amino]-5-oxopentanoic acid
6-[[4-(3,4-dihydro-2H-quinolin-1-ylsulfonyl)anilino]-oxomethyl]-1-cyclohex-3-enecarboxylic acid
4,5-Dimethoxy-2-[[1-oxo-2-[(3,5,8-trimethyl-2-quinolinyl)thio]ethyl]amino]benzoic acid
2-(3,5-Dinitrophenyl)-3-(2-phenylethyl)imidazo[4,5-b]quinoxaline
2-[N-(benzenesulfonyl)-4-ethoxyanilino]-N-(2-methoxyphenyl)acetamide
(1R,9S,10S,11S)-5-(3-fluorophenyl)-10-(hydroxymethyl)-12-methyl-6-oxo-N-(1,3-thiazol-2-yl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-5-(3-fluorophenyl)-10-(hydroxymethyl)-12-methyl-6-oxo-N-(1,3-thiazol-2-yl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,3R,8S,9R,10S,13S,16S,17R)-8-Tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
2-amino-5-[[3-[(Z)-C-benzyl-N-hydroxycarbonimidoyl]sulfanyl-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
(1S,3R,6R,7S,8S,9R,10S,11R,12S,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
(1S,3R,6R,7S,8S,9R,10S,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.0(1),(1)(1).0(3),.0,(1)(1).0(1)(3),(1)]nonadecane-5,15,18-trione
(1R,6R,7S,8S,9S,10S,11R,12R,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
(1S,3R,6R,7S,8S,9R,10S,11R,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
(1R,6R,7R,8S,9S,10S,11R,12R,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
AZD4747
AZD4747 is a selective, blood-brain barrier-permeable mutant GTPase KRASG12C inhibitor. AZD4747 has the potential to study cancer[1].
PF-06372865
PF-06372865 is an orally active, α2/α3/α5 subtype-selective GABAA positive allosteric modulator (PAM). PF-06372865 is a high affinity ligand at GABAA receptors containing α1/α2/α3/α5 subunits (Kis of 2.9 nM, 21 nM, 134 nM for α2, α1 PAM, α2 PAM, respectively), with low affinity for α4/α6 subunits. PF-06372865 can across the blood-brain barrier (BBB). PF-06372865 has anxiolytic activity and has the potential for epilepsy[1].